
Shares of contract drug development company Integer Holdings ITGR.N fall 2.9% to $139.02 in morning trade
Company expects 2025 adj. profit to be between $5.84 and $6.20 per share, with the midpoint below analysts' estimates of $6.07, according to data compiled by LSEG
ITGR posts Q4 profit of $1.43 per share, slightly below analysts' estimates of $1.46 per share
Company says markets sales decreased 17% in Q4 2024 compared to a year ago, after the exit from its portable medical unit, which was announced in 2022
Company expects to close the acquisition of waterproof electronic coating maker VSi Parylene for about $28 million by the end of this month
ITGR has risen ~39% in the last 12 months